Last reviewed · How we verify
Recombivax
At a glance
| Generic name | Recombivax |
|---|---|
| Also known as | There are no other names., Hepatitis B vaccine |
| Sponsor | University of North Carolina, Chapel Hill |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PHASE3)
- HepB-CpG Series for Healthcare Workers Who Are Hepatitis B Vaccine Nonresponders (PHASE4)
- Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029) (PHASE3)
- A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION) (PHASE3)
- A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers (PHASE2)
- Effects of Persistent Innate Immune Activation on Vaccine Efficacy (PHASE4)
- Hepatitis B Vaccine in Seniors (EARLY_PHASE1)
- A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Recombivax CI brief — competitive landscape report
- Recombivax updates RSS · CI watch RSS
- University of North Carolina, Chapel Hill portfolio CI